



(11) **EP 2 431 050 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 71

(51) Int Cl.:
A61K 38/20 ^(2006.01) **A61K 39/395** ^(2006.01)
C07K 16/28 ^(2006.01) **C07K 16/32** ^(2006.01)

(48) Corrigendum issued on:
26.09.2012 Bulletin 2012/39

(43) Date of publication:
21.03.2012 Bulletin 2012/12

(21) Application number: **11184743.0**

(22) Date of filing: **20.05.2005**

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

(30) Priority: **20.05.2004 US 572973 P**
10.12.2004 US 635380 P
14.04.2005 US 671281 P
12.05.2005 US 680447 P

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
05756320.7 / 1 758 610

(71) Applicant: **ZymoGenetics, Inc.**
Seattle, Washington 98102 (US)

(72) Inventors:
• **Kindsvogel, Wayne, R.**
Seattle, WA 98115 (US)
• **Hughes, Steven D.**
Kenmore, WA 98028 (US)
• **Holly, Richard D.**
Seattle, WA 98177 (US)

• **Clegg, Christopher H.**
Seattle, WA 98177 (US)
• **Foster, Donald C.**
Lake Forest Park, WA 98155 (US)
• **Johnson, Rebecca A.**
Seattle, WA 98136 (US)
• **Heipel, Mark D.**
Seattle, WA 98177 (US)
• **Sivakumar, Pallavur V.**
Seattle, WA 98112 (US)


(74) Representative: **Griffin, Philippa Jane**
Mathys & Squire LLP
120 Holborn
London
EC1N 2SQ (GB)

Remarks:

This application was filed on 11-10-2011 as a divisional application to the application mentioned under INID code 62.

(54) **Methods of treating cancer using IL-21 and monoclonal antibody therapy**

(57) There is provided a monoclonal antibody that binds to a Her-2/neu receptor, and an IL-21 polypeptide or fragment of an IL-21 polypeptide as shown in SEQ ID NO:2 from amino acid residue 30 to residue 162, for use in treating cancer in a subject, wherein the subject has 1+ or 2+ overexpression levels of the Her-2/neu receptor



EP 2 431 050 A8